TEMPUS AI, INC. CLASS A COMMON STOCK

NASDAQ: TEM (Tempus AI, Inc.)

最近更新时间: 19小时之前

77.03

3.25 (4.40%)

前收盘价格 73.78
收盘价格 72.36
成交量 9,478,318
平均成交量 (3个月) 11,979,372
市值 13,382,267,904
市盈率 (P/E TTM) 35.83
价格/销量 (P/S) 13.46
股市价格/股市净资产 (P/B) 41.41
52周波幅
31.36 (-59%) — 91.45 (18%)
利润日期 3 Nov 2025
营业毛利率 -88.27%
营业利益率 (TTM) -26.93%
稀释每股收益 (EPS TTM) -5.16
季度收入增长率 (YOY) 75.40%
总债务/股东权益 (D/E MRQ) 262.96%
流动比率 (MRQ) 1.71
营业现金流 (OCF TTM) -193.29 M
杠杆自由现金流 (LFCF TTM) 54.30 M
资产报酬率 (ROA TTM) -43.89%

市场趋势

短期 中期
行业 Health Information Services (US) 看涨 混合的
Health Information Services (全球的) 看涨 混合的
股票 Tempus AI, Inc. 看跌 看涨

AIStockmoo 评分

-0.4
分析师共识 -5.0
内部交易活动 NA
价格波动 -3.0
技术平均移动指标 2.5
技术振荡指标 4.0
平均 -0.38

相关股票

股票 市值 DY P/E(TTM) P/B
TEM 13 B - 35.83 41.41
HQY 8 B - 67.04 3.74
WAY 6 B - 64.71 1.90
RCM 6 B - - 2.14
PRVA 3 B - 191.25 3.78
WGS 3 B - - 10.90

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

部门 Healthcare
行业 Health Information Services
投资方式 Small Growth
内部持股比例 43.27%
机构持股比例 38.33%

所有权

姓名 日期 持有股份
Softbank Group Corp. 30 Jun 2025 5,405,406
Sumitomo Mitsui Trust Group, Inc. 30 Jun 2025 3,869,941
Nikko Asset Management Americas, Inc. 30 Jun 2025 3,869,941
Revolution Growth Management Company, Inc. 31 Mar 2025 1,467,565
52周波幅
31.36 (-59%) — 91.45 (18%)
目标价格波幅
68.00 (-11%) — 75.00 (-2%)
75.00 (Guggenheim, -2.64%) 购买
70.00 (-9.13%)
68.00 (Morgan Stanley, -11.72%) 购买
平均值 71.00 (-7.83%)
总计 2 购买, 1 保留
平均价格@调整类型 65.12
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 12 Aug 2025 68.00 (-11.72%) 购买 66.34
Guggenheim 30 Jun 2025 75.00 (-2.64%) 购买 63.54
B of A Securities 25 Jun 2025 70.00 (-9.13%) 保留 65.47
20 May 2025 68.00 (-11.72%) 保留 62.43

该时间范围内无数据。

日期 类型 细节
08 Aug 2025 公告 Tempus Reports Second Quarter 2025 Results
22 Jul 2025 公告 Tempus to Report Second Quarter 2025 Financial Results on August 8
16 Jul 2025 公告 Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
16 Jul 2025 公告 From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine
09 Jul 2025 公告 Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
08 Jul 2025 公告 Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
30 Jun 2025 公告 Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
30 Jun 2025 公告 Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
25 Jun 2025 公告 Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
17 Jun 2025 公告 Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
13 Jun 2025 公告 Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
12 Jun 2025 公告 Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
02 Jun 2025 公告 Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
01 Jun 2025 公告 Introducing Tempus One in the EHR with Integrated Guidelines
31 May 2025 公告 Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
30 May 2025 公告 Real-World Deployments Signal AI Healthcare Is Ready for Scale
30 May 2025 公告 Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
28 May 2025 公告 A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
28 May 2025 公告 Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: TEM)
21 May 2025 公告 Tempus to Present at the William Blair 45th Annual Growth Stock Conference
21 May 2025 公告 Options Trading Now Available on Three Tradr ETFs: QBTX, TEMT and APPX
20 May 2025 公告 Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
20 May 2025 公告 From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票